S&P 500   4,283.64 (-0.10%)
DOW   33,401.65 (-0.32%)
QQQ   360.26 (+0.56%)
AAPL   172.88 (+0.98%)
MSFT   318.62 (+0.91%)
META   305.69 (+1.83%)
GOOGL   132.76 (+1.45%)
AMZN   127.86 (+0.58%)
TSLA   246.72 (-1.40%)
NVDA   446.51 (+2.65%)
NIO   8.98 (-0.66%)
BABA   86.63 (-0.13%)
AMD   103.38 (+0.54%)
T   14.97 (-0.33%)
F   12.38 (-0.32%)
MU   69.00 (+1.43%)
CGC   0.79 (+1.23%)
GE   110.72 (+0.15%)
DIS   81.00 (-0.06%)
AMC   8.23 (+3.00%)
PFE   32.88 (-0.87%)
PYPL   58.87 (+0.70%)
NFLX   379.46 (+0.49%)
S&P 500   4,283.64 (-0.10%)
DOW   33,401.65 (-0.32%)
QQQ   360.26 (+0.56%)
AAPL   172.88 (+0.98%)
MSFT   318.62 (+0.91%)
META   305.69 (+1.83%)
GOOGL   132.76 (+1.45%)
AMZN   127.86 (+0.58%)
TSLA   246.72 (-1.40%)
NVDA   446.51 (+2.65%)
NIO   8.98 (-0.66%)
BABA   86.63 (-0.13%)
AMD   103.38 (+0.54%)
T   14.97 (-0.33%)
F   12.38 (-0.32%)
MU   69.00 (+1.43%)
CGC   0.79 (+1.23%)
GE   110.72 (+0.15%)
DIS   81.00 (-0.06%)
AMC   8.23 (+3.00%)
PFE   32.88 (-0.87%)
PYPL   58.87 (+0.70%)
NFLX   379.46 (+0.49%)
S&P 500   4,283.64 (-0.10%)
DOW   33,401.65 (-0.32%)
QQQ   360.26 (+0.56%)
AAPL   172.88 (+0.98%)
MSFT   318.62 (+0.91%)
META   305.69 (+1.83%)
GOOGL   132.76 (+1.45%)
AMZN   127.86 (+0.58%)
TSLA   246.72 (-1.40%)
NVDA   446.51 (+2.65%)
NIO   8.98 (-0.66%)
BABA   86.63 (-0.13%)
AMD   103.38 (+0.54%)
T   14.97 (-0.33%)
F   12.38 (-0.32%)
MU   69.00 (+1.43%)
CGC   0.79 (+1.23%)
GE   110.72 (+0.15%)
DIS   81.00 (-0.06%)
AMC   8.23 (+3.00%)
PFE   32.88 (-0.87%)
PYPL   58.87 (+0.70%)
NFLX   379.46 (+0.49%)
S&P 500   4,283.64 (-0.10%)
DOW   33,401.65 (-0.32%)
QQQ   360.26 (+0.56%)
AAPL   172.88 (+0.98%)
MSFT   318.62 (+0.91%)
META   305.69 (+1.83%)
GOOGL   132.76 (+1.45%)
AMZN   127.86 (+0.58%)
TSLA   246.72 (-1.40%)
NVDA   446.51 (+2.65%)
NIO   8.98 (-0.66%)
BABA   86.63 (-0.13%)
AMD   103.38 (+0.54%)
T   14.97 (-0.33%)
F   12.38 (-0.32%)
MU   69.00 (+1.43%)
CGC   0.79 (+1.23%)
GE   110.72 (+0.15%)
DIS   81.00 (-0.06%)
AMC   8.23 (+3.00%)
PFE   32.88 (-0.87%)
PYPL   58.87 (+0.70%)
NFLX   379.46 (+0.49%)
CVE:HEM

Hemostemix (HEM) Stock Forecast, Price & News

C$0.12
+0.01 (+4.35%)
(As of 09/29/2023 05:42 PM ET)
Compare
Today's Range
C$0.11
▼
C$0.12
50-Day Range
C$0.11
▼
C$0.17
52-Week Range
C$0.10
▼
C$0.28
Volume
53,500 shs
Average Volume
56,083 shs
Market Capitalization
C$10.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsInsider TradesHeadlines

HEM stock logo

About Hemostemix (CVE:HEM) Stock

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

HEM Price History

HEM Stock News Headlines

August 29, 2023 | finance.yahoo.com
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications
August 8, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc up on Friday (HEM)
October 2, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
June 28, 2023 | finanznachrichten.de
Hemostemix Inc.: Hemostemix Closes $403,539 of the Unit Private Placement
June 28, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc up on Tuesday (HEM)
June 28, 2023 | finance.yahoo.com
Hemostemix Closes $403,539 of the Unit Private Placement
June 27, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc down on Monday (HEM)
June 24, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc flat on Wednesday (HEM)
October 2, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
June 22, 2023 | marketwatch.com
Hemostemix's Private Placement Use of Proceeds
June 17, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc down on Friday (HEM)
June 2, 2023 | msn.com
Hemostemix to raise $1.2M through private placement of units
May 3, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc flat on Tuesday (HEM)
May 2, 2023 | finance.yahoo.com
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company
April 29, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc flat on Friday (HEM)
April 21, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc flat on Thursday (HEM)
April 20, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc up on Wednesday (HEM)
April 19, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc down on Tuesday (HEM)
April 18, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc up on Monday (HEM)
April 13, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc down on Wednesday (HEM)
April 7, 2023 | theglobeandmail.com
Closing Bell: Hemostemix Inc up on Thursday (HEM)
April 3, 2023 | finance.yahoo.com
Hemostemix' Second Round Interviews with Executive Vice President Business Development Candidates
March 29, 2023 | finance.yahoo.com
Peripheral Artery Disease Market to Showcase Growth at a Paltry CAGR of 4% During the Study Period (2019-2032) | DelveInsight
March 21, 2023 | finance.yahoo.com
Hemostemix Closes $762,400 of The Unit Private Placement
March 8, 2023 | finance.yahoo.com
Hemostemix Unit Offering Repriced
January 31, 2023 | yahoo.com
The Force Family Office Engaged by Hemostemix
January 30, 2023 | finance.yahoo.com
Hemostemix' "Your Fountain of Youth" Trademark Granted by Switzerland
See More Headlines
Receive HEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
CVE:HEM
CUSIP
N/A
CIK
N/A
Web
www.hemostemix.com
Phone
+1-403-3409207
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
C($0.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-3,720,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-338.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.12
Quick Ratio
0.48

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$0.01 per share
Price / Cash Flow
10.77
Book Value
C($0.08) per share
Price / Book
-1.50

Miscellaneous

Outstanding Shares
84,450,000
Free Float
N/A
Market Cap
C$10.13 million
Optionable
Not Optionable
Beta
0.66
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Thomas A. Smeenk B.A. (Age 61)
    BA Hons, Co-Founder, Pres, CEO & Director
    Comp: $308k
  • Ms. Christina Wu CPA
    Interim Chief Financial Officer
  • Peter Pavlin
    VP of Operations
  • Dr. Fraser C. Henderson Sr.
    M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













HEM Stock - Frequently Asked Questions

How have HEM shares performed in 2023?

Hemostemix's stock was trading at C$0.18 at the beginning of the year. Since then, HEM stock has decreased by 33.3% and is now trading at C$0.12.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Hemostemix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hemostemix investors own include Iplayco (IPC), Capricor Therapeutics (CAPR), Gene Biotherapeutics (CRXM), Camber Energy (CEI), Auxly Cannabis Group (CBWTF), Cannabis Science (CBIS), Beazer Homes USA (BZH), Big Tree Group (BIGG), Asterias Biotherapeutics (AST) and

What is Hemostemix's stock symbol?

Hemostemix trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HEM."

How do I buy shares of Hemostemix?

Shares of HEM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Hemostemix's stock price today?

One share of HEM stock can currently be purchased for approximately C$0.12.

How much money does Hemostemix make?

Hemostemix (CVE:HEM) has a market capitalization of C$10.13 million. The biotechnology company earns C$-3,720,000.00 in net income (profit) each year or C($0.04) on an earnings per share basis.

How can I contact Hemostemix?

Hemostemix's mailing address is Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada. The official website for the company is www.hemostemix.com. The biotechnology company can be reached via phone at +1-403-3409207.

This page (CVE:HEM) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -